Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Monotherapy vs Entecavir Plus Tenofovir in Chronic Hepatitis B
NCT03236610Phase 3Unknown
- Sponsor
- Uijeongbu St. Mary's Hospital
- Start
- Jan 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenofovir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Uijeongbu St. Mary's Hospital. Primary endpoint: Sustained Virological Response at 48 weeks. Status: unknown.
02
Drugs
tenofovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03236610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236610.